Posted by Michael Wonder on 25 Aug 2022
Janssen marks first approval worldwide for Tecvayli (teclistamab) with EC authorisation of first in class bispecific antibody for the treatment of patients with multiple myeloma
24 August 2022 - Teclistamab, an off the shelf subcutaneously administered therapy, induced deep and rapid responses in triple class exposed patients with relapsed and refractory multiple myeloma.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted conditional marketing authorisation of Tecvayli (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma.
